Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Infectious Disease
•
General Infectious Disease
•
General Hospital Medicine
Do you ever favor cefazolin over ceftriaxone for bacteremia with susceptible E. coli?
Answer from: at Community Practice
No
Sign In
or
Register
to read more
Answer from: at Community Practice
We do cefazolin often unless h/o ESBL or complicated infection or procedural history. It is our preferred abx for pyelo or intra-abdominal infection (we add Flagyl for intra-abdominal) and is driven by our local susceptibility data.
Sign In
or
Register
to read more
Answer from: at Community Practice
No, I prefer 3rd generation Cephalosporins(or higher) for gram negatives.
Sign In
or
Register
to read more
Answer from: at Community Practice
Typically no.
Sign In
or
Register
to read more
24951
28385
28336
28415
Related Questions
How would you manage a patient with necrotizing pneumonia due to a susceptible Pseudomonas aeruginosa strain who continues to have significant purulent secretions and worsening imaging while receiving cefepime?
Do you consider use of oral antibiotics for complicated polymicrobial intra-abdominal infections?
With OpenBiome no longer in operation, what is your current approach for obtaining FMT for inpatients with acute severe/fulminant C. difficile infection unresponsive to antibiotics?
How long do you treat Staphylococcus aureus pyomyositis with antibiotics?
How do you typically manage a patient with a single positive blood culture from two sets growing Candida species in a stable patient without prosthetic devices or material?
How do you manage gram-negative bacteremia in a patient with an aortic bypass graft, for whom there is low clinical suspicion for active graft infection?
How would you approach troponin testing and cardiac monitoring for hospitalized patients with Mycoplasma pneumonia, given recent findings of significant cardiac involvement?
How does trimethoprim-sulfamethoxazole's efficacy against S. pyogenes influence your empirical treatment of skin infections in regions with high resistance rates?
Do you routinely recommend transition to dual PO antibiotic coverage for strep species and MRSA, for patients with purulent cellulitis and in the absence of culture data?
Do you routinely use cefdinir for the treatment of common infections diagnosed in the outpatient setting such as CAP, uncomplicated UTIs?